Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study

Abstract Background and Objective Patients with heart failure or cardio/renal dysfunction (chronic kidney disease, end-stage kidney disease, or heart failure) are at increased risk of hyperkalemia. Sodium zirconium cyclosilicate (SZC) treats hyperkalemia, but the impact of SZC treatment duration on...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Abiy Agiro, Fan Mu, Erin E. Cook, Ali Greatsinger, Jingyi Chen, Manasvi Sundar, Angela Zhao, Ellen Colman, Arun Malhotra
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2025-10-01
coleção:	Drugs - Real World Outcomes
Acesso em linha:	https://doi.org/10.1007/s40801-025-00525-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!